SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
OpenAI Restricts Astra AI Over Cyberattack Risks 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
TUSTIN, Calif., March 06, 2018 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that its president and chief executive officer, Roger J. Lias, Ph.D., will deliver a corporate presentation at the 30th Annual ROTH Conference. The conference is being held March 11-14, 2018 at the Ritz-Carlton Laguna Niguel in Dana Point, CA.
Details of this presentation are as follows:
- 30th Annual ROTH Conference
Time/Date: 2:00 p.m. PT on Tuesday, March 13, 2018
Location: Ritz-Carlton Laguna Niguel, Dana Point, CA
Room: Yellow Salon 6
Avid’s presentation at the ROTH conference will be webcast live and available for replay at: http://ir.avidbio.com/events.cfm.
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
